August 10, 2016 / 12:17 PM / in a year

BRIEF-Arch Biopartners to manufacture drug AB569 with Catalent Inhalation

Aug 10 (Reuters) - Arch Biopartners Inc :

* Engaged Catalent Inhalation, a division of Catalent Pharma Solutions, to begin manufacturing process for drug ab569

* Catalent Inhalation to undertake initial stability and formulation studies, later manufacture a supply of ab569

* Engaged Catalent Inhalation in preparation for first human trials involving patients with antibiotic resistant lung infections Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below